Covid-19 - The Search for Effective Therapy.
作者信息
Baden Lindsey R, Rubin Eric J
出版信息
N Engl J Med. 2020 May 7;382(19):1851-1852. doi: 10.1056/NEJMe2005477. Epub 2020 Mar 18.
Abstract
摘要
相似文献
1
Covid-19 - The Search for Effective Therapy.新冠病毒-19：寻找有效疗法
N Engl J Med. 2020 May 7;382(19):1851-1852. doi: 10.1056/NEJMe2005477. Epub 2020 Mar 18.
2
Early triple antiviral therapy for COVID-19.新冠肺炎的早期三联抗病毒治疗
Lancet. 2020 Nov 7;396(10261):1487-1488. doi: 10.1016/S0140-6736(20)32274-1.
3
Early triple antiviral therapy for COVID-19 - Authors' reply.COVID-19的早期三联抗病毒治疗——作者回复
Lancet. 2020 Nov 7;396(10261):1488. doi: 10.1016/S0140-6736(20)32268-6.
4
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?洛匹那韦/利托那韦在新冠病毒感染中的应用：是否完全无益？
J Microbiol Immunol Infect. 2020 Oct;53(5):674-675. doi: 10.1016/j.jmii.2020.05.014. Epub 2020 May 25.
5
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2：洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
6
Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.洛匹那韦/利托那韦联合疗法用于印度有症状的 2019 冠状病毒病患者：限制公共卫生紧急使用的方案。
Indian J Med Res. 2020;151(2 & 3):184-189. doi: 10.4103/ijmr.IJMR_502_20.
7
SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.新型冠状病毒感染患者使用诺华芬治疗后清除病毒效果：一项随机、开放标签、平行分组试验。
Int J Infect Dis. 2020 Oct;99:84-91. doi: 10.1016/j.ijid.2020.07.053. Epub 2020 Aug 3.
8
The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.利好、弊端与骗局：当发表的内容瞬间影响新冠疫情治疗策略时
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.01127-20.
9
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.洛匹那韦/利托那韦未能缩短台湾轻症肺炎患者 SARS-CoV-2 脱落持续时间。
J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.
10
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.洛匹那韦利托那韦治疗的 2 例 COVID-19 患者出现血清素综合征。
J Neurol Sci. 2020 Aug 15;415:116944. doi: 10.1016/j.jns.2020.116944. Epub 2020 May 27.
引用本文的文献
1
Moloney Murine Leukemia Virus-like Nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for Vaccination Against COVID-19.用严重急性呼吸综合征冠状病毒2受体结合域假型化的莫洛尼鼠白血病病毒样纳米颗粒用于预防2019冠状病毒病的疫苗接种。
Int J Mol Sci. 2025 Jul 4;26(13):6462. doi: 10.3390/ijms26136462.
2
[Colchicine, an old friend's perspectives for rheumatology in COVID-19: a scoping review].[秋水仙碱：老朋友对COVID-19中风湿病学的看法：一项范围综述]
Rev Colomb Reumatol. 2022 Jun;29:S35-S47. doi: 10.1016/j.rcreu.2021.02.002. Epub 2021 Mar 27.
3
Remdesivir associated with reduced mortality in hospitalized COVID-19 patients: treatment effectiveness using real-world data and natural language processing.瑞德西韦与住院COVID-19患者死亡率降低相关：利用真实世界数据和自然语言处理的治疗效果
BMC Infect Dis. 2025 Apr 12;25(1):513. doi: 10.1186/s12879-025-10817-6.
4
[Treatment of the COVID-19 pandemic: Preventing a missed opportunity].[新冠疫情的治疗：防止错失良机]
Rev Clin Esp. 2020 Aug-Sep;220(6):386-387. doi: 10.1016/j.rce.2020.04.005. Epub 2020 Apr 15.
5
Acute and subacute oral toxicity characterization and safety assessment of COVID organics (Madagascar's Anti-COVID Herbal Tea) in animal models.新型冠状病毒有机物（马达加斯加抗新冠草药茶）在动物模型中的急、亚急性经口毒性特征及安全性评价。
Ann Afr Med. 2023 Oct-Dec;22(4):481-488. doi: 10.4103/aam.aam_112_21.
6
Ritonavir Has Reproductive Toxicity Depending on Disrupting PI3K/PDK1/AKT Signaling Pathway.利托那韦具有生殖毒性，这取决于其对PI3K/PDK1/AKT信号通路的干扰。
Toxics. 2024 Jan 15;12(1):73. doi: 10.3390/toxics12010073.
7
A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2.抗逆转录病毒（洛匹那韦/利托那韦）和瑞德西韦在伊拉克大流行期间用于治疗 SARS-CoV-2 患者的临床疗效比较研究。
Arch Razi Inst. 2023 Jun 30;78(3):935-941. doi: 10.22092/ARI.2022.360354.2574. eCollection 2023 Jun.
8
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.新型冠状病毒肺炎（COVID-19）：严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）变异株概述——当前疫苗和药物研发进展。
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.
9
Metabolome and transcriptome analyses identify the characteristics and expression of related saponins of the three genealogical plants of bead ginseng.代谢组学和转录组学分析鉴定了三种人参属植物中相关皂苷的特征和表达。
PeerJ. 2023 Sep 1;11:e16034. doi: 10.7717/peerj.16034. eCollection 2023.
10
Potential Drugs in COVID-19 Management.新冠病毒管理中的潜在药物。
Curr Med Chem. 2024;31(22):3245-3264. doi: 10.2174/0929867331666230717154101.
本文引用的文献
1
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
2
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.比较瑞德西韦与洛匹那韦利托那韦和干扰素β联合治疗中东呼吸综合征冠状病毒的疗效。
Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.
3
We Can Do Better - Improving Outcomes in the Midst of an Emergency.我们可以做得更好——在紧急情况下改善治疗效果。
N Engl J Med. 2017 Oct 12;377(15):1482-1484. doi: 10.1056/NEJMe1712330.
Zotero 插件